20-Hydroxyvitamin D 3 inhibits proliferation of cancer cells with high efficacy while being non-toxic

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 739-746

  Wang, Jin ^a   Slominski, Andrzej ^a   Tuckey, Robert C ^a   Janjetovic, Zorica ^a   Kulkarni, Anand ^a   Chen, Jianjun ^a   Postlethwaite, Arnold E ^b,c   Miller, Duane ^a   Li, Wei ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c CHRISTIAN BROTHERS UNIVERSITY   (United States)

Author keywords

20 Hydroxyvitamin d 3; Antiproliferative activity; Colony formation; HepG2 cells; Hypercalcemic effect; MCF7 cells

Indexed keywords

20 HYDROXYVITAMIN D3; ANTINEOPLASTIC AGENT; CALCITRIOL; COLECALCIFEROL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CALCIFEDIOL; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; NEOPLASMS;

EID: 84863390379     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Spina CS, Tangpricha V, Uskokovic M, Adorinic L, Maehr H and Holick MF: Vitamin D and cancer. Anticancer Res 26: 2515-2524, 2006. (Pubitemid 44155530)
2. Takahashi T, and Morikawa K: Vitamin D receptor agonists: opportunities and challenges in drug discovery. Curr Top Med Chem 6: 1303-1316, 2006. (Pubitemid 44110919)
3. Pinette KV, Yee YK, Amegadzie BY and Nagpal S: Vitamin D receptor as a drug discovery target. Mini Rev Med Chem 3: 193-204, 2003.
4. Slominski A, Semak I, Zjawiony J, Wortsman J, Li W, Szczesniewski A and Tuckey RC: The cytochrome P450scc system opens an alternate pathway of vitamin D3 metabolism. FEBS J 272: 4080-4090, 2005. (Pubitemid 41160916)
5. 3 hydroxylation by cytochrome P450scc, stimulates keratinocyte differentiation. J Invest Dermatol 128: 2271-2280, 2008.
6. 3 by cytochrome P450scc. FEBS J 275: 2585-2596, 2008.
7. 2. FEBS J 273: 2891-2901, 2006.
8. 2 is a noncalcemic analog of vitamin D with potent antiproliferative and prodifferentiation activities in normal and malignant cells. American J of Physiology Cell physiology 300: C526-541, 2011.
9. Slominski AT, Li W, Bhattacharya SK, Smith RA, Johnson PL, Chen J, Nelson KE, Tuckey RC, Miller D, Jiao Y, Gu W and Postlethwaite AE: Vitamin D analogs 17,20S(OH)2pD and 17,20R(OH)2pD are noncalcemic and exhibit antifibrotic activity. J Invest Dermatol 131: 1167-1169, 2011.
10. 3, novel P450scc product, stimulates differentiation and inhibits proliferation and NF-kappaB activity in human keratinocytes. J Cell Physiol 223: 36-48, 2010.
11. 3 hydroxylation by P450scc, decreases NF-kappaB activity by increasing IkappaB alpha levels in human keratinocytes. PLoS One 4: e5988, 2009.
12. 3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show anti-leukemia effects, having low or absent calcemic activity. PLoS One 5: e9907, 2010.
13. 3 derivatives. British journal of cancer 105: 1874-1884, 2011.
14. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ and Strippoli GF: Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 147: 840-853, 2007. (Pubitemid 351664426)
15. Tuckey RC, Li W, Shehabi HZ, Janjetovic Z, Nguyen MN, Kim TK, Chen J, Howell DE, Benson HA, Sweatman T, Baldisseri DM and Slominski A: Production of 22-hydroxy metabolites of vitamin d3 by cytochrome p450scc (CYP11A1) and analysis of their biological activities on skin cells. Drug Metab Dispos 39: 1577-1588, 2011.
16. 3, which shows antiproliferative activity. Steroids 75: 926-935, 2010.
17. Slominski AT, Zmijewski MA, Semak I, Sweatman T, Janjetovic Z, Li W, Zjawiony JK and Tuckey RC: Sequential metabolism of 7-dehydrocholesterol to steroidal 5,7-dienes in adrenal glands and its biological implication in the skin. PLoS One 4: e4309, 2009.
18. 3 analogues: disassociation of their prominent antileukemic effects from their lack of calcium modulation. Cancer Res 61: 3361-3368, 2001.
19. Adams JS and Hewison M: Update in vitamin D. J Clin Endocrinol Metab 95: 471-478, 2010.
20. Krishnan AV and Feldman D: Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 51: 311-336, 2011.
21. Nagpal S, Na S and Rathnachalam R: Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 26: 662-687, 2005. (Pubitemid 41127276)
22. Ma Y, Trump DL and Johnson CS: Vitamin D in combination cancer treatment. J Cancer 1: 101-107, 2010.
23. Hoffman RM: In vitro sensitivity assays in cancer: a review, analysis, and prognosis. J Clin Lab Anal 5: 133-143, 1991.